发明授权
- 专利标题: Imidazo[1,2-C]pyrimidinylacetic acid derivatives
- 专利标题(中): 咪唑并[1,2-C]嘧啶基乙酸衍生物
-
申请号: US10585429申请日: 2005-01-19
-
公开(公告)号: US07750014B2公开(公告)日: 2010-07-06
- 发明人: Tai-Wei Ly , Takashi Yoshino , Yuki Takekawa , Takuya Shintani , Hiromi Sugimoto , Kevin Bacon , Klaus Urbahns
- 申请人: Tai-Wei Ly , Takashi Yoshino , Yuki Takekawa , Takuya Shintani , Hiromi Sugimoto , Kevin Bacon , Klaus Urbahns
- 申请人地址: US CA San Diego
- 专利权人: Actimis Pharmaceuticals, Inc.
- 当前专利权人: Actimis Pharmaceuticals, Inc.
- 当前专利权人地址: US CA San Diego
- 代理机构: Jones Day
- 优先权: EP04002144 20040131
- 国际申请: PCT/EP2005/000475 WO 20050119
- 国际公布: WO2005/073234 WO 20051108
- 主分类号: A01N43/90
- IPC分类号: A01N43/90 ; A61K31/519 ; C07D487/00
摘要:
The present invention relates to an imidazo[1,2-c]pyrimidinylacetic acid derivative and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The imidazo[1,2-c]pyrimidinylacetic acid derivative of the present invention has excellent CRTH2 (G-protein-coupled chemoattractant receptor, expressed on Th2 cells) antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with CRTH2 activity, in particular for the treatment of allergic diseases, such as asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis; eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis; basophil-related diseases, such as basophilic leukemia, chronic urticaria and basophilic leukocytosis in human and other mammals; and inflammatory diseases characterized by T lymphocytes and profuse leukocyte infiltrates such as psoriasis, eczema, inflammatory bowel disease, ulcerative colitis, Crohn's disease, COPD (chronic obstructive pulmonary disorder) and arthritis.
公开/授权文献
- US20090012102A1 Imidazo[1,2-C]Pyrimidinylacetic Acid Derivatives 公开/授权日:2009-01-08